Placebo-controlled trials of Chinese herbal medicine and conventional medicine—comparative study by Shang, Aijing et al.
Placebo-controlled trials of Chinese herbal
medicine and conventional medicine—
comparative study
Aijing Shang,1 Karin Huwiler,1 Linda Nartey,1 Peter Ju¨ni1,2 and Matthias Egger1,3*
Accepted 4 May 2007
Background Chinese herbal medicine (CHM) is increasingly used in the West, but the
evidence on its effectiveness is a matter of debate. We compared the charac-
teristics, study quality and results of clinical trials of CHM and conventional
medicine.
Methods Comparative study of placebo-controlled trials of CHM and conventional
medicine. Eleven bibliographic databases and searches by hand of 48 Chinese-
language journals. Conventional medicine trials matched for condition and type
of outcome were randomly selected from the Cochrane Controlled Trials Register
(issue 1, 2003). Trials described as double-blind, with adequate generation of
allocation sequence and adequate concealment of allocation, were assumed to
be of high quality. Data were analysed using funnel plots and multivariable
meta-regression models.
Results 136 CHM trials (119 published in Chinese, 17 published in English) and 136
matched conventional medicine trials (125 published in English) were analysed.
The quality of Chinese-language CHM trials tended to be lower than that of
English-language CHM trials and conventional medicine trials. Three (2%) CHM
trials and 10 (7%) conventional medicine trials were of high quality. In all
groups, smaller trials showed more beneficial treatment effects than larger trials.
CHM trials published in Chinese showed considerably larger effects than CHM
trials published in English (adjusted ratio of ORs 0.29, 95% confidence intervals
0.17–0.52).
Conclusions Biases are present both in placebo-controlled trials of CHM and conventional
medicine, but may be most pronounced in CHM trials published in Chinese-
language journals. Only few CHM trials of adequate methodology exist and the
effectiveness of CHM therefore remains poorly documented.
Introduction
Traditional Chinese medicine (TCM) is a system of health care
with a unique theoretical and diagnostic basis that originated
in China some 2500 years ago. The core concepts suggest that
disease is the result of imbalances in the flow of the body’s vital
energy, or ‘qi’ (pronounced ‘chee’), and that the human body is
a microcosm of the basic natural forces at work in the universe.
In modern China, both TCM and conventional medicine
are practised, with TCM accounting for about 40% of all
health care delivered.1 TCM is also increasingly popular in
industrialized countries.2,3 Acupuncture and Chinese herbal
medicine (CHM) are most widely used both in China and
in the West.
Although TCM has a long history, its effectiveness continues
to be debated. The evidence on CHM is particularly contro-
versial. Common criticisms include the poor methodological
quality of trials, and the biased dissemination of their
results.4–7 The situation is complicated by the fact that many
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clinical trials in CHM are published in Chinese, and therefore
inaccessible to most Western researchers.8
Bias in the conduct and reporting of trials is a possible
explanation for positive findings of both placebo-controlled
trials of CHM and conventional medicine.5,9,10 We compared
the characteristics and results of placebo-controlled trials of
CHM, including trials published in Chinese, with a matched
sample of conventional medicine trials, and assessed the quality
of trials and publication and related biases.
Methods
Literature searches
We searched 11 electronic databases, covering the periods from
inception to January 2003: MEDLINE, EMBASE, CINAHL,
AMED, MANTIS, Toxline, PASCAL, BIOL, Science Citation
Index, CENTRAL and SIGLE. The search terms in MEDLINE
were [‘Medicine, Chinese Traditional’(MESH) and phytotherap
or herbal or herb or herbs or ‘plant extracts’ or ‘plant extract’]
or [‘Drugs, Chinese Herbal’(MESH) or ‘Chinese herbs’ or
‘Chinese herb’] and [placebo or placebos(mesh) or ‘placebo
effect’(mesh) or sham]. Search terms were similar for the other
databases. We checked the reference lists of relevant articles
and contacted experts in the field. No language restrictions
were used.
Since many medical journals published in China are
inaccessible in Europe, we performed additional searches at
Shanghai University of Traditional Chinese Medicine. We used
CBMdisc, a Chinese-language electronic database, to identify
journals that publish clinical trials of CHM. CBMdisc goes back
to 1980 and is the most comprehensive and accessible literature
database in China. We found 63 potentially eligible trials,
which were published in 27 TCM journals and 16 conventional
medicine journals. Library staff in Shanghai indicated that an
additional five TCM journals might be relevant. With local help
(Acknowledgements section), we therefore searched 48 journals
by hand. Since few placebo-controlled trials were published
before 1990, all issues from January 1990 to March 2003 were
searched, except for two journals: ‘Zhongguo Zhong Xi Yi Jie
He Za Zhi’ and ‘Zhong Yi Za Zhi’. These two journals are the
leading Chinese-language journals in TCM and were searched
back to 1980.
We searched the Cochrane Central Controlled Trials Register
(CENTRAL) to identify a matched placebo-controlled trial of
conventional medicine for each eligible CHM trial, using
keywords relevant to condition and outcome. CENTRAL is
a bibliographic database of controlled trials maintained by
the Cochrane Collaboration.11 We searched issue 1, 2003 of
CENTRAL which contained 353 809 bibliographic references.
Study selection
We defined inclusion and exclusion criteria a priori and applied
the same criteria to trials of CHM and conventional medicine.
Inclusion criteria were (i) controlled trials of treatments or
preventative measures with clinical outcomes, (ii) parallel
group design with placebo control, (iii) available written
report, such as a journal publication, abstract, thesis,
conference proceeding, unpublished report, book chapter or
monograph and (iv) sufficient information to allow the
calculation of odds ratios (ORs). We excluded cross-over
trials, trials in healthy volunteers and N-of-1 trials.
Selection of outcomes and matching procedures
We used pre-specified criteria for identifying outcomes for
inclusion in analysis. The first choice was the main outcome
measure, which was defined as the outcome used for sample
size calculations. If a main outcome was not specified,
we selected alternative outcomes, in the following order:
(i) patients’ global assessment of improvement; (ii) physicians’
global assessment of improvement; (iii) the clinically most
relevant other outcome measure (for example, the occurrence
or duration of an illness). Outcomes were selected at random
if several outcomes were considered equally relevant.
For each CHM trial, we identified matching trials of
conventional medicine, which enrolled patients with similar
conditions and assessed similar outcomes. We used computer-
generated random numbers to select one out of several
eligible trials of conventional medicine. Selection of outcomes
and matching of trials was done without knowledge of trial
results.
Data extraction and definitions
We used a piloted data extraction sheet. Except for Chinese-
language trials, which were assessed only by one of us (AS),
data extraction was done independently by two observers, with
discrepancies being resolved by consensus. CHM was classified
into individualized therapy, partially individualized therapy,
non-individualized therapy and unclear type of CHM. In
trials of individualized therapies, remedies were chosen
according to individual signs and symptoms. Partially individ-
ualized therapy consisted of a basic remedy that was used for
all patients and individualized by adding or omitting some
herbs. If all patients used the same remedy, the intervention
was defined as non-individualized. Diagnosis was based
on TCM (for example, ‘qi’ deficiency), Western diagnosis
(for example, hypertension) or a combination of the two.
Other information collected on CHM interventions included
whether Chinese names of herbs were mentioned, whether the
dosage of each herb was reported and whether remedies were
changed during the study.
Assessment of study quality
Assessment of study quality focused on key domains of internal
validity:9,12 randomization (generation of allocation sequence
and concealment of allocation) and blinding (of patients,
therapists and outcome assessors). Use of a random-number
table, computer-generated random numbers, minimization, coin
tossing, shuffling cards and drawing lots were classified as
adequate methods for the generation of the allocation sequence.
Sealed, opaque sequentially numbered assignment envelopes,
central randomization, independently prepared and coded drug
packs of identical appearance, and on-site computerized
randomization systems were considered adequate methods of
allocation concealment. Descriptions of other methods were
coded either as inadequate or unclear, pending on the level of
detail provided. Trials described as double-blind, describing
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adequate methods for the generation of allocation sequence and
adequate concealment of allocation were classified as of high
methodological quality.
Graphical and statistical analysis
CHM trials and conventional medicine trials were analysed
separately. We expressed results of each trial on the OR scale
and used the method described by Hasselblad and Hedges13 to
convert differences in continuous outcomes to ORs. We recoded
outcomes if necessary, so that ORs <1 always indicated
a beneficial effect of treatment. We examined heterogeneity
between trials using the I-squared statistic.14 We investigated
the association between study size and trial results in funnel
plots, by plotting ORs on the horizontal axis (on a logarithmic
scale) against their standard errors on the vertical axis.15
The extent to which study-level variables were associated
with log ORs was examined by fitting univariable and multi-
variable meta-regression models separately for CHM trials
and conventional medicine trials.16 The following variables
were considered: standard error of log OR, language and year
of publication, indexing of publication in MEDLINE and
trial quality (blinding, generation of allocation sequence and
concealment of allocation).
Results are given as ORs, ratios of ORs or asymmetry
coefficients with 95% confidence intervals (95% CI).
Ratios of ORs of <1 correspond to a smaller OR for trials
with the characteristic and hence a larger apparent benefit of
the intervention. Funnel plot asymmetry was measured
by the asymmetry coefficient: the ratio of ORs per unit increase
in standard error of log OR.17 All analyses were performed
in Stata version 9.0 (Stata Corporation, College Station,
TX, USA).
Results
We identified 334 potentially eligible reports of placebo-
controlled trials of CHM and excluded 199 reports. The
most frequent reasons for exclusion were other type of
intervention examined, no clinical outcomes reported and
no placebo group (Figure 1). We included 135 publications,
which reported on a total of 136 independent trials of CHM
and 136 publications of 136 matched trials of conven-
tional medicine. The bibliographic details of these trials are
given in Appendices 1 and 2 (available at: www.ispm.ch/
downloads).
Trial characteristics
Cardiovascular, gynaecological and obstetrical disorders were
the most common conditions studied in pairs of trials of CHM
and conventional medicine (Table 1). Close matching of
outcomes was not possible in some instances, leading, for
example, to global assessments of response being analysed in
66 (49%) of CHM trials, but only in 51 (38%) of trials
of conventional medicine (Table 2).
The characteristics of CHM trials depended on language of
publication: trials published in Chinese had larger sample sizes
but were less likely to be indexed in MEDLINE than CHM trials
published in English. The reported methodological quality of
Chinese-language CHM trials tended to be lower than that of
English-language CHM trials. Only one CHM trial published in
Chinese and two CHM trials published in English were
classified as of high methodological quality. Conventional
medicine trials published in other languages tended to be
smaller (median sample size 39 compared with 60) but there
were few differences regarding methodological quality. Only 10
(7%) conventional medicine trials were of high quality
(Table 2).
Characteristics of CHM interventions are presented in Table 3.
The majority of trials was based on Western diagnosis (103,
76%). Most CHM remedies were taken orally. Reporting
of the names of herbs was incomplete in 74 (55%) trials
and only few trials (34, 25%) described the preparation of
remedies. A change of remedies during follow-up was not
reported in any trial. Only two trials identified interventions
as individualized CHM, three were partially individualized.
Most conventional medicine trials examined drugs (125, 92%),
seven (5%) were concerned with vitamins or dietary
199 publications excluded:
Not Chinese Herbal Medicine (n=39)
No clinical outcome (n=38)
Not placebo-controlled (n=31)
Duplicate publication (n=18)
Trial in healthy volunteers (n=17)
Ineligible study design (n=15)
Unclear outcome measure (n=14)
No matching trial available (n=12)
Insufficient information (n=7)
Other(n=8)
334 potentially eligible
       publications identified
       from literature search 
135 publications reporting
       on 136 trials of       
       Chinese Herbal
       Medicine included   
Figure 1 Identification of 136 eligible placebo-controlled trials of
Chinese herbal medicine that could be matched to an equal number of
placebo-controlled trials of conventional medicine
Table 1 Distribution of pairs in Chinese Herbal Medicine and matched
conventional medicine trials across clinical areas
Clinical area No of trial pairs
Cardiovascular disease 16 (12%)
Gynaecology and obstetrics 16 (12%)
Neurology 13 (9.6%)
Surgery and anaesthesiology 13 (9.6%)
Oncology 11 (8.1%)
Respiratory diseases 10 (7.3%)
Gastroenterology 10 (7.3%)
Asthma and Pollinosis 9 (6.6%)
Dermatology 8 (5.9%)
Other 30 (22%)
1088 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
supplements, two with the evaluation of a vaccine and two
with immunotherapy.
Graphical and statistical analyses of treatment
effects
Most ORs indicated a beneficial effect of the intervention.
The degree of between-trial heterogeneity was similar for CHM
and for conventional medicine. The proportion of total variation
in the estimates of treatment effects due to between-study
heterogeneity (I-squared)18 was 83% for CHM and 84%
for conventional medicine.
Funnel plots were asymmetrical, with smaller trials
(larger SEs) in the lower part of the plot showing more
beneficial treatment effects than larger trials (smaller SEs,
Figure 2). In meta-regression models, the association between
SEs and treatment effects was stronger for CHM trials
published in Chinese than trials published in English: the
asymmetry coefficients were 0.09 (95% CI 0.04–0.17) and 0.38
(95% CI 0.06–2.31), respectively. Therefore, for each unit
increase in the SE, the OR decreased by a factor of 0.09
for Chinese-language CHM trials and factor 0.38 for English-
language CHM trials. The asymmetry coefficient was 0.29
(95% CI 0.14–0.61) for conventional medicine.
In meta-regression analyses, the standard error of the log OR
(asymmetry coefficient) was the dominant variable in both
groups. In CHM (but not in conventional medicine) language
of publication continued to be an important, independent
predictor of treatment effects. The ratio of ORs comparing
Chinese with English CHM trials was 0.28 (95% CI 0.15–0.52)
in univariable analysis and 0.29 (95% CI 0.17–0.52) in multi-
variable analysis adjusted for the standard error of the log OR.
In multivariable analyses of both the CHM and conventional
medicine trials, there was little evidence (P40.10) for an
association of treatment effects with other variables, including
study quality.
Table 2 Characteristics of placebo-controlled trials of Chinese herbal medicine and conventional medicine
Chinese herbal medicine trials (n¼ 136)
Published in
Chinese (n¼ 119)
Published in
English (n¼ 17)
Conventional medicine
trials (n¼ 136)
Sample size
Median (range) 86 (24–8025) 50 (12–720) 59.5 (8–6500)
Mean (SD) 207 (778) 113 (182) 192 (674)
Median year of publication (range) 1998 (1984–2003) 1998 (1989–2002) 1994 (1974–2002)
Type of publication
English language 0 (0%) 17 (100%) 125 (92%)
Journal 119 (100%) 17 (100%) 136 (100%)
Medline-indexed 27 (23%) 16 (94%) 124 (91%)
Type of outcome
Global assessment of response 60 (50%) 6 (35%) 51 (38%)
Occurrence or duration of condition 37 (31%) 3 (18%) 42 (31%)
Assessment of symptoms 7 (5.9%) 6 (35%) 18 (13%)
Measurement of function or state 13 (11%) 1 (5.9%) 22 (16%)
Assessment of clinical signs 2 (1.7%) 1 (5.9%) 3 (2.2%)
Trial quality
Blinding
Described as ‘double-blind’ 41 (34%) 15 (88%) 127 (93%)
Describes blinding of
Outcome assessors 14 (12%) 6 (35%) 35 (26%)
Patients 13 (11%) 6 (35%) 22 (16%)
Therapists 15 (13%) 3 (18%) 23 (17%)
Generation of allocation sequence
Adequate 16 (13%) 6 (35%) 29 (21%)
Inadequate 19 (16%) 0 (0%) 1 (1%)
Unclear 84 (71%) 11 (65%) 106 (78%)
Concealment of allocation
Adequate 5 (4%) 7 (41%) 17 (12%)
Inadequate 0 (0%) 0 (0%) 0 (0%)
Unclear 114 (96%) 10 (59%) 119 (88%)
High quality 1 (0.8%) 2 (12%) 10 (7.4%)
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Discussion
We compared the characteristics and quality of published
placebo-controlled trials of CHM with comparable trials of
conventional medicine and examined the presence of bias
due to inadequate methodology and selective publication.
We found that, in general, smaller trials showed more
beneficial effects than larger trials. In trials of CHM, study
quality and results depended on language of publication: CHM
trials published in English were of higher methodological
quality and showed smaller effects than trials published in
Chinese. There were very few placebo-controlled trials of CHM
with adequate methodology. It is therefore not possible, based
on the currently available placebo-controlled trials of CHM
to confirm or exclude beneficial effects of CHM. Similarly,
most of the placebo-controlled trials of conventional medicine
had methodological deficiencies and only few trials were
of high quality.
Strengths and weaknesses
To our knowledge, this is the first study directly comparing the
presence of biases and their influence on effect estimates
from clinical trials of CHM and conventional medicine.
Our electronic search of the literature was comprehensive
Table 3 Characteristics of Chinese herbal medicine
interventions
Category
Chinese herbal
medicine trials (n¼ 136)
Diagnostic systems
Traditional Chinese only 0
Western only 103 (76%)
Both 33 (24%)
Way of application
Oral 98 (72%)
Intravenously 3 (2.2%)
Transdermal 18 (13%)
Transrectal 9 (6.6%)
Other 8 (5.9%)
Galenic form
Tablet 26 (19%)
Capsule 22 (16%)
Drops 1 (0.7%)
Decoction 21 (15%)
Other 66 (49%)
Name of herbs reported
Yes, for all 62 (45%)
Yes, for some 54 (40%)
No 20 (15%)
Dosage of each herb mentioned
Yes 44 (32%)
No 92 (68%)
Preparation described
Yes 34 (25%)
No 102 (75%)
Change of remedies
Yes 0 (0)
No 134 (99%)
Unclear 2 (1.5%)
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Figure 2 Funnel plot of 119 trials of Chinese herbal medicine
published in Chinese (upper panel), 17 Chinese herbal medicine
published in English (middle panel) and 136 matched conventional
medicine trials (lower panel)
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and, importantly, complemented by an extensive search by
hand of a large number of journals published in China. Indeed,
most of the trials were published in Chinese and identified
through the search conducted in China. We acknowledge that
the identification of unpublished studies, or studies not indexed
in the relevant databases is notoriously difficult, and it is
possible that we missed some unpublished trials, for example
trials published in Japanese or Korean. Conventional medicine
trials were randomly selected from the largest existing database
of clinical trials (the Cochrane CENTRAL registry), and
matched to herbal medicine trials for clinical area and type
of outcome.
A limitation of our review is the focus on the beneficial
effects of CHM and conventional medicine, rather than on both
benefits and risks. However, the trials included in our study
were small and lacked the power to reveal infrequent but
important adverse effects. Furthermore, reporting on adverse
effects has been shown to be inadequate even in larger trials.19
It is, therefore, unlikely that a comprehensive and valid
assessment of adverse effects would have been possible
within the framework of the present study. We stress that we
did not examine the validity of the complex diagnostic system
that is part of CHM.
Different sources of bias are difficult to disentangle.
The methodological quality of randomized trials cannot reliably
be assessed from published articles because reporting on
important aspects of methodology is often incomplete, and
the quality of reporting is an inadequate proxy measure
for methodological quality.12,20 Deficiencies in methodology of
smaller trials that were either not reported by the authors or
not assessed by us may therefore have contributed to the
asymmetrical shape of the funnel plots. Small studies of CHM
may show more beneficial effects than larger ones because it is
more feasible in small studies to treat patients individually and
change remedies according to the change of their symptoms.
However, none of the 136 trial reports mentioned changes in
remedies during follow up and only two trials were identified
as using individualized treatments.
Findings in context with other studies
In a similar study, we recently compared placebo-controlled trials
of homoeopathy and conventional medicine.21 In contrast to the
present study, the degree of funnel plot asymmetry was similar in
trials of homoeopathy and conventional medicine. Trials of
homoeopathy tended to be of higher methodological quality
than conventional medicine trials, although most trials of either
type of medicine were also of low or uncertain quality. Vickers
and colleagues,22 in a review of controlled studies examined
whether certain countries produce only positive results. They
found that published clinical trials conducted in China almost
never report an experimental treatment to be equal or inferior
to control. Our results confirm their findings for placebo-
controlled trials of CHM and indicate that greater publication
bias and the lower methodological quality of trials conducted in
China might explain this phenomenon.
Tang and co-workers8 identified almost 3000 randomized con-
trolled trials in a search of 28 Chinese journals of traditional
Chinese medicine. Most trials examined herbal treatments, how-
ever, they generally compared two herbal preparations and did
not express effectiveness in numerical terms.8 Our search covered
48 Chinese journals, but we identified only 136 parallel-group,
placebo-controlled trials with clinically relevant and quantifiable
outcomes. In line with Tang et al.’s survey8, most Chinese-
language clinical trials of CHM were not placebo-controlled.
Several systematic reviews of trials of CHM have been done
by the Cochrane Collaboration and other groups in recent years.
The conclusions make depressive reading: ‘based on one low
quality trial, the medicinal herb . . .may have an antiviral
activity;’23 ‘Because the trial methodology of these studies
was often inadequate or insufficiently documented, it is
difficult to recommend the use of CHMs . . . ,’6 ‘At present, it
is unclear whether Chinese herbal treatments . . . do more good
than harm.’7 These conclusions are not surprising in the light of
our study: if only very few large high-quality trials exist, then
systematic reviews of individual CHM interventions will be
based on a few small trials of low quality.
Implications and future research
We agree with Ernst24 that in the light of the popularity of
herbal medicine, more research is required to clarify the proper
place of herbalism, including CHM, in modern health care
systems. Both large high-quality randomized trials to examine
the effectiveness, or otherwise, of herbal preparations, and
research that aims to identify the active component or
components of herbal medicines are needed.
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KEY MESSAGES
 A comprehensive search of the international and Chinese literature identified 136 placebo-controlled clinical trials of
traditional CHM.
 Trials of CHM published in English were of higher methodological quality and showed smaller effects than trials
published in Chinese.
 Only few trials of adequate methodology exist and the effectiveness of CHM therefore remains poorly documented.
 More research is required to clarify the place of CHM in modern health care systems.
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